Cancers
Cure8 research brief
Advanced Therapies for the Management of Immune Checkpoint Inhibitor-Induced Colitis
Medications
Biomarkers
Drug Discovery
Biomarker
Systematic Review or Meta Analysis
Inflammatory bowel disease
Why This Matters
Patients receiving immune checkpoint inhibitors can develop ICI‑induced colitis that resembles IBD and may not respond to steroids. This review discusses advanced biologic and targeted therapies used when steroids fail, which directly affects management and quality of life.
The evidence base is limited and mostly retrospective, so findings guide but do not definitively establish best treatment sequences or long‑term safety.
Who Should Pay Attention
Oncologists, gastroenterologists, clinicians treating ICI toxicities, researchers in immune‑related adverse events, and patients receiving ICIs or biologic therapy for steroid‑refractory colitis.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The article reports that corticosteroids are first-line for ICI‑colitis but a substantial minority are steroid-refractory. Infliximab (anti‑TNF) and vedolizumab (anti‑integrin) are highlighted as effective salvage therapies, with infliximab linked to faster symptom control and vedolizumab to steroid‑sparing benefit.
For multi‑refractory cases, limited evidence from small series supports agents including ustekinumab and tofacitinib; however, data are sparse and mainly retrospective. The review emphasizes that most evidence is retrospective and that prospective randomized trials are needed, especially studies that measure both cancer outcomes and GI endpoints.
It also notes interest in biomarker and mechanistic research to guide therapy selection.
Keep In Mind
Structured-content depth for this source is abstract-level; the review synthesizes mostly retrospective studies and case series. Prospective randomized data and biomarker‑driven guidance are still lacking. Interpret conclusions accordingly.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCancers
PublisherMDPI AG
AuthorsCosimo Simone Matichecchia, Fabrizio Fanizzi, Alessandra Zilli +7 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedSep 24, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Connecting the Dots Between Pharmacokinetics, Inflammatory Biomarkers, and Mucosal Healing in Patients on Infliximab with Inflammatory Bowel Disease
If true, using infliximab drug-level modeling plus routine blood tests could help predict who has mucosal healing without immediate endoscopy, potentially reducing invasive procedures and improving monitoring for people...
Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms.
Many people with IBD also have overweight or obesity; GLP-1 receptor agonists are being used for weight loss and may affect inflammation and IBD outcomes. This review summarizes current evidence on safety, effectiveness,...
Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn’s Disease
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...